Results of the satellite symposium “What does it cost us to build a house? Immunotherapy of acute lymphoblastic leukemia in pediatric practice”, held on November 23, 2023 within the framework of the IV Joint Congress of RSPOH “Actual problems and prospects for the development of pediatric oncology and hematology in the Russian Federation – 2023”

1. Benjamin J.E., Stein A.S. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol. 2016;7(3):142–56. doi: 10.1177/2040620716640422.

2. Queudeville M., Ebiger M. Blinatumomab in pediatric acute lymphoblastic leukemia – from salvage to fi rst line therapy (a systematic review). J Clin Med. 2021;10(12):2544. doi: 10.3390/jcm10122544.

3. Rallis K.S., Hillyar C.R.T., Sideris M., Davies J.K. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecifi c T-Cell Engagers (BiTEs). Anticancer Res. 2021;41(3):1123–41. doi: 10.21873/anticanres.14870.

4. Majhail N.S., Mau L.W., Chitphakdithai P., Denzen E.M., Joff e S., Lee S.J., LeMaistre C.F., Loberiza F., Parsons S.K., Repaczki-Jones R., Robinett P., Rizzo J.D., Murphy E., Logan B., Le-Rademacher J. Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. Bone Marrow Transplant. 2020;55(5):906–17. doi: 10.1038/s41409-019-0748-1.

5. Gratwohl A., Baldomero H., Aljurf M., Pasquini M.C., Bouzas L.F., Yoshimi A., Szer J., Lipton J., Schwendener A., Gratwohl M., Frauendorfer K., Niederwieser D., Horowitz M., Kodera Y.; Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617–24. doi: 10.1001/jama.2010.491.